Maxim Group set a $12.00 price target on Cytosorbents (NASDAQ:CTSO) in a report released on Monday. The firm currently has a buy rating on the medical research company’s stock.

Several other research firms have also commented on CTSO. HC Wainwright reiterated a buy rating and set a $13.00 price objective on shares of Cytosorbents in a research note on Tuesday, November 21st. B. Riley reiterated a buy rating and set a $11.25 price objective on shares of Cytosorbents in a research note on Friday, November 10th. Finally, ValuEngine lowered Cytosorbents from a hold rating to a sell rating in a research note on Monday, October 2nd. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $10.45.

Shares of Cytosorbents (NASDAQ:CTSO) opened at $6.65 on Monday. Cytosorbents has a 52 week low of $3.30 and a 52 week high of $7.05. The company has a quick ratio of 3.17, a current ratio of 3.36 and a debt-to-equity ratio of 0.73.

In other news, COO Vincent Capponi sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, November 27th. The stock was sold at an average price of $7.00, for a total value of $28,000.00. Following the completion of the sale, the chief operating officer now directly owns 271,062 shares in the company, valued at $1,897,434. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 5.60% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the company. Fortaleza Asset Management Inc. grew its position in shares of Cytosorbents by 81.6% in the third quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock valued at $145,000 after purchasing an additional 10,500 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Cytosorbents by 145.2% in the second quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock valued at $163,000 after purchasing an additional 22,500 shares in the last quarter. Finally, Wealthcare Advisory Partners LLC acquired a new position in Cytosorbents in the third quarter valued at approximately $365,000. Institutional investors and hedge funds own 8.65% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Cytosorbents (CTSO) Given a $12.00 Price Target at Maxim Group” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/12/cytosorbents-ctso-given-a-12-00-price-target-at-maxim-group.html.

About Cytosorbents

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Analyst Recommendations for Cytosorbents (NASDAQ:CTSO)

Receive News & Stock Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related stocks with our FREE daily email newsletter.